You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK-rearranged

Showing 1 - 25 of 393
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

Recruiting
  • Non-small Cell Lung Cancer Stage IIIB
  • ALK Gene Mutation
  • Alectinib Oral Product
  • Mexico City, Mexico
    Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
Jan 26, 2023

ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

Not yet recruiting
  • ALK Gene Mutation
  • +2 more
  • Pembrolizumab Combined With Bevacizumab and Chemotherapy
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jul 14, 2022

Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • IBI-322 Plus Lenvatinib and Platinum
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 14, 2022

ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 31, 2023

First Line Crizotinib for ALK Rearranged Non-squamous Non-small

Recruiting
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

Completed
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 23, 2021

Chemotherapy Combined With Immunotherapy or Chemotherapy

Completed
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 9, 2022

NSCLC Trial in United States (brigatinib)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • Denver, Colorado
  • +3 more
Jan 10, 2023

Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Middletown, New Jersey
  • +5 more
Aug 17, 2023

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 4, 2022

Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Withdrawn
  • Non-Small Cell Lung Cancer
  • InVisionFirst-Lung ctDNA assay
  • Los Angeles, California
  • +2 more
Sep 16, 2022

NSCLC Trial in Boston (Alectinib, Cobimetinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 7, 2021

NSCLC, ALK Gene Rearrangement Positive Trial in France (RNAseq)

Recruiting
  • Non-small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • RNAseq
  • Saint-Denis, La Réunion, France
  • +44 more
Nov 4, 2021

Anaplastic Lymphoma Kinase (ALK), NSCLC Trial in Worldwide (LDK378, AUY922)

Completed
  • Anaplastic Lymphoma Kinase (ALK)
  • Non-small Cell Lung Cancer
  • Aurora, Colorado
  • +7 more
Dec 16, 2020

Lung Cancer Trial in Boston (Carboplatin, Nivolumab, pemetrexed)

Completed
Has Results
  • Lung Cancer
  • Boston, Massachusetts
  • +2 more
Oct 14, 2020

NSCLC Trial in Worldwide (Ceritinib, pemetrexed, docetaxel)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +96 more
Dec 19, 2022

ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Irvine, California
  • +3 more
Aug 30, 2021

NSCLC (NSCLC) Trial in Boston (Lorlatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 7, 2021

NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

Terminated
  • Non-small Cell Lung Cancer
  • Davis, California
  • +1 more
Dec 22, 2022

NSCLC Trial in Worldwide (Ceritinib, Pemetrexed, Cisplatin)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Woolloongabba, Queensland, Australia
  • +131 more
Oct 24, 2022

NSCLC Trial in Worldwide (ceritinib)

Completed
  • Non-Small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +72 more
Feb 7, 2022

NSCLC Trial in France (Alectinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Angers, France
  • +15 more
Feb 7, 2020

NUT Midline Carcinoma, Triple Negative Breast Cancer, NSCLC With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Trial

Completed
Has Results
  • NUT Midline Carcinoma
  • +5 more
  • (no location specified)
Jan 7, 2021

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Unknown status
  • Non Small Cell Lung Cancer
  • +2 more
    • Camaiore, Lucca, Italy
    • +22 more
    Mar 24, 2020